Abstract
Available descriptive statistics for patients with metastatic basal cell carcinoma (mBCC) are limited. To describe disease characteristics, treatment patterns, survival outcomes, and prognostic factors of patients with mBCC, we conducted a retrospective review of electronic health records in the Department of Veterans Affairs (VA). The primary outcome was survival. Data were also collected on demographics, comorbidities, medications, and procedures. Median (IQR) age of patients with mBCC (n = 475) was 72.0 (17.0) years; 97.9% of patients were male. Almost two-thirds of patients received no initial therapy for mBCC. Median overall survival was 40.5 months [95% CI (confidence interval) 4.8–140.0], and was shorter in patients with distant metastases (17.1 months; 95% CI 2.8–58.0) than in those with regional metastases (59.4 months; 95% CI 17.6–140.0). Because the VA mBCC population is largely male and elderly, the generalizability of these results in other populations is limited and must be interpreted cautiously. Data from this large cohort add valuable information on a rare and poorly researched disease and refine previously wide estimates of overall survival for mBCC.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 505-513 |
| Number of pages | 9 |
| Journal | Archives of Dermatological Research |
| Volume | 310 |
| Issue number | 6 |
| DOIs | |
| State | Published - Aug 1 2018 |
| Externally published | Yes |
Bibliographical note
Funding Information:Third-party medical writing support was provided by Melanie Sweetlove, MSc, and Jennifer M. Kulak, PhD (ApotheCom, San Francisco, CA), and funded by F. Hoffmann-La Roche Ltd. SLD and OVP have received research funding through the University of Utah or Western Institute for Biomedical Research from the following for-profit organizations: Amgen Inc., AbbVie Inc., Anolinx LLC, AstraZeneca Pharmaceuticals LP, F. Hoffmann-La Roche Ltd, Genentech Inc., Genomic Health, Inc., Gilead Sciences Inc., HITEKS Solutions Inc., LexisNexis Risk Solutions, Merck & Co., Inc., Mylan Specialty LP, Northrop Grumman Information Systems, Novartis International AG, PAREXEL International Corporation, and Shire PLC. YMM and RM are employees of Genentech. VWS has received research funding through the University of Utah from Anolinx LLC, Merck & Co., Inc., and Pfizer Inc. DDS has received research funding through the University of Utah from the following for-profit organizations: Genentech Inc., AstraZeneca Pharmaceuticals LP, Myriad Genetics, Bristol-Myers Squibb, AbbVie Inc., and Novartis International AG. He has served as a paid consultant to the following for-profit organizations: Bristol-Myers Squibb, Myriad Genetics, Salarius Pharmaceuticals, and BetaCat Pharmaceuticals. AK is an owner of Anolinx.
Funding Information:
Acknowledgements Third-party medical writing support was provided by Melanie Sweetlove, MSc, and Jennifer M. Kulak, PhD (ApotheCom, San Francisco, CA), and funded by F. Hoffmann-La Roche Ltd.
Publisher Copyright:
© 2018, This is a U.S. Government work and not under copyright protection in the US; foreign copyright protection may apply.
Keywords
- Epidemiology
- Incidence
- Metastatic basal cell carcinoma
- Survival
- Treatment
- Veterans
